Iterum aims for early ORLYNVAH launch in August 2025 and eyes expansion in $40M uUTI market
Source: SeekingAlpha
2025-08-05 16:59:18 ET
More on Iterum Therapeutics
- Iterum Therapeutics plc (ITRM) Q2 2025 Earnings Call Transcript
- Iterum Therapeutics plc (ITRM) Q1 2025 Earnings Call Transcript
- Iterum Therapeutics Non-GAAP EPS of -$0.13
- Iterum targets ORLYNVAH US launch by Q4 2025 while extending cash runway into 2026
- Seeking Alpha’s Quant Rating on Iterum Therapeutics
Read the full article on Seeking Alpha
For further details see:
Iterum aims for early ORLYNVAH launch in August 2025 and eyes expansion in $40M uUTI market
Iterum Therapeutics plc
NASDAQ: ITRM
ITRM Trading
-0.29% G/L:
$0.1702 Last:
327,061 Volume:
$0.171 Open:
ITRM Latest News
ITRM Stock Data
$15,988,461
51,778,499
0.46%
14
N/A
Biotechnology & Life Sciences
Healthcare
IE
Dublin 1
